SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001737287-24-000003
Filing Date
2024-01-31
Accepted
2024-01-30 18:43:37
Documents
14
Period of Report
2024-01-25
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K allo-20240125.htm   iXBRL 8-K 31204
  Complete submission text file 0001737287-24-000003.txt   160048

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20240125.xsd EX-101.SCH 1989
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20240125_lab.xml EX-101.LAB 24139
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20240125_pre.xml EX-101.PRE 12595
15 EXTRACTED XBRL INSTANCE DOCUMENT allo-20240125_htm.xml XML 2763
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 24580046
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)